Zobrazeno 1 - 10
of 30
pro vyhledávání: '"Benjamin, Eades"'
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1103-1108 (2020)
A 52-year-old African-American woman with a prior history of monoclonal gammopathy of undetermined significance (MGUS) developed infiltrating ductal carcinoma of the left breast. Following a mastectomy, she underwent reconstruction with a silicone ge
Externí odkaz:
https://doaj.org/article/826fbfe1a7a841b68084ea08d94f9e16
Autor:
Shahrooz Eshaghian, James R. Berenson, Gary T. Schwartz, Stephen Lim, Robert Vescio, Benjamin Eades, Tanya M. Spektor, Matthew Ghermezi, David Yashar, Daisy Martinez, Regina A. Swift
Publikováno v:
Leukemia & Lymphoma. 63:975-983
High-risk multiple myeloma (MM) continues to have a poor prognosis and remains a therapeutic challenge. This phase 2 study evaluated the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib, and low-dose dexamethasone for p
Autor:
Gary T. Schwartz, Marsiye Emamy-Sadr, Tanya M. Spektor, Benjamin Eades, Bernard Regidor, Jessica Wang, Marissa-Skye Goldwater, Shahrooz Eshagian, Sean Bujarski, Regina A. Swift, James R. Berenson
Publikováno v:
Annals of Hematology. 100:2061-2070
Venetoclax is a BCL-2 inhibitor currently indicated for use in treating hematologic malignancies with recommended doses ranging from 400 to 600 mg/day. Although currently not FDA-approved to treat multiple myeloma (MM) patients, there is a growing nu
Autor:
Marsiye Emamy-Sadr, James R. Berenson, Tanya M. Spektor, Bernard Regidor, Benjamin Eades, Regina A. Swift, Fadi Tarhini
Publikováno v:
Annals of Hematology. 100:1079-1085
The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a serum
Autor:
James Wang, Tanya M. Spektor, Regina A. Swift, Benjamin Eades, Chace Henning, James R. Berenson
Publikováno v:
Case Reports in Oncology, Vol 13, Iss 3, Pp 1103-1108 (2020)
Case Reports in Oncology
Case Reports in Oncology
A 52-year-old African-American woman with a prior history of monoclonal gammopathy of undetermined significance (MGUS) developed infiltrating ductal carcinoma of the left breast. Following a mastectomy, she underwent reconstruction with a silicone ge
Autor:
Chace Henning, Regina A. Swift, Letantia Bussell, Tanya M. Spektor, James R. Berenson, Benjamin Eades, Sydney Meyers
Publikováno v:
Clinical Lymphoma Myeloma and Leukemia. 20:e492-e495
Autor:
David Daniely, Benjamin Eades, Marissa-Skye Goldwater, Eric Souther, Ning Xu, Marsiye Emamy-Sadr, Tanya M. Spektor, Cathy Wang, Haiming Chen, Scott Jew, Bernard Regidor, Regina A. Swift, Sean Bujarski, Mingjie Li, James R. Berenson
Publikováno v:
European journal of haematologyREFERENCES. 107(3)
Background Multiple myeloma (MM) patients with smoldering (S) disease are defined by a lack of CRAB/SLiM criteria but may transform into disease requiring treatment. The International Myeloma Working Group risk stratification model for SMM uses serum
Autor:
Bernard, Regidor, Regina, Swift, Benjamin, Eades, Marsiye, Emamy-Sadr, Fadi, Tarhini, Tanya M, Spektor, James R, Berenson
Publikováno v:
Annals of hematology. 100(4)
The purpose of this single-center retrospective study was to determine the incidence of decreased blood phosphorus levels and hypophosphatemia among multiple myeloma (MM) patients treated with elotuzumab. Hypophosphatemia, which is defined as a serum
Autor:
James R. Berenson, Sydney Meyers, Tanya M. Spektor, Benjamin Eades, Chace Henning, Regina A. Swift
Publikováno v:
Clinical lymphoma, myelomaleukemia. 20(11)
Autor:
James R. Berenson, Daisy Martinez, Tahmineh Safaie, Noemi Silagan, Jennifer To, Tanya M. Spektor, Eli Forouzan, Regina Swift, Benjamin Eades, Shahrooz Eshaghian, Gary Schwartz, Ralph V. Boccia, Honghao H Yang, Mehdi M. Moezi, Stephen Lim, Robert Vescio
Publikováno v:
Blood. 138:2727-2727
Introduction Ruxolitinib (RUX) is an FDA-approved oral, selective inhibitor of Janus kinase (JAK) 1/2 for the treatment of patients with intermediate or high-risk myelofibrosis and polycythemia vera who have had an inadequate response to or are intol